Enliven Therapeutics, Inc. ((ELVN)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Enliven Therapeutics, Inc. is currently conducting a Phase 1a/1b clinical study titled ‘A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia.’ The study aims to evaluate the safety, tolerability, and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia (CML), particularly those with and without T315I mutations who are relapsed, refractory, or intolerant to tyrosine kinase inhibitors (TKIs).
The intervention being tested is ELVN-001, an experimental drug administered orally once or twice daily. Its purpose is to achieve a deep molecular response in CML patients who do not tolerate or benefit from available TKIs.
The study is interventional with a non-randomized, sequential intervention model and no masking. Its primary purpose is treatment, focusing on determining the recommended dose for expansion in CML patients.
The study began on May 22, 2022, and the latest update was submitted on July 14, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
This update could potentially impact Enliven Therapeutics’ stock performance positively, as successful results may enhance investor sentiment and position the company favorably against competitors in the CML treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.